Drug Profile
Metenkefalin/tridecactide - Farmacija
Alternative Names: EK-12; EnkortenLatest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator Farmacija
- Developer Bosnalijek
- Class Analgesics; Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Neuropeptides
- Mechanism of Action Leukocyte stimulants; Opioid delta receptor agonists; Th1 cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple sclerosis
- Phase III Asthma
- Phase II/III COVID 2019 infections
- Phase II Crohn's disease; Ulcerative colitis
- No development reported Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 22 Sep 2022 Metenkefalin/tridecactide is still in phase III and phase I/II trials for Multiple sclerosis and COVID-2019 infections in Turkey and Bosnia-Herzegovina (NCT03283397) (NCT04374032)
- 01 May 2020 Phase-II/III clinical trials in COVID-2019 infections in Bosnia-Herzegovina (SC) (NCT04374032)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Bosnia-Herzegovina (SC, Injection)